IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: :

Bernd RIEDL et al. : Group Art Unit: TO BE ASSIGNED

Serial No.: TO BE ASSIGNED : Examiner: TO BE ASSIGNED

Filed: November 27, 2001 :

For: ω-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the accompanying application as follows.

IN THE SPECIFICATION

Page 1, line 1, after the title insert

--Priority is claimed to provisional application Serial No. Unassigned, filed on November 28, 2000.--

IN THE CLAIMS

Please cancel claims 1-54, 60-67 without prejudice or disclaimer.

Please amend claims 55-59 as follows.

Claim 55. (Amended) A pharmaceutical composition comprising a compound of claim 69 ~~1 or a pharmaceutically acceptable salt of a compound of formula I~~, and a physiologically acceptable carrier.

Claim 56. (Amended) A pharmaceutical composition comprising a compound of claim 70 ~~2 consistent with formula I or a pharmaceutically acceptable salt thereof~~, and a physiologically acceptable carrier.

Claim 57. (Amended) A pharmaceutical composition comprising a compound of

claim 71 ~~33 consistent with formula I or a pharmaceutically acceptable salt thereof,~~ and a physiologically acceptable carrier.

Claim 58. (Amended) A pharmaceutical composition comprising a compound of claim 72 ~~38 consistent with formula I or a pharmaceutically acceptable salt thereof,~~ and a physiologically acceptable carrier.

Claim 59. (Amended) A pharmaceutical composition comprising a compound of claim 73 ~~39 consistent with formula I or a pharmaceutically acceptable salt thereof~~ and a physiologically acceptable carrier.

Please add new claims 68-98 as follows.

--68. A compound selected from the group consisting of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

69. The compound

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

70. The compound

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

71. The compound

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

72. The compound

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

73. The compound

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

74. A method for the treatment of a cancerous cell growth mediated by RAF kinase comprising administering a compound selected from the group consisting of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-

pyridyloxy)phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

75. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(5-tert-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methyl carbamoyl)phenoxy)phenyl) urea.

76. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

77. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

78. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

79. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

80. A method as in claim 79 for the treatment of solid cancers.

81. A method as in claim 74 for the treatment of carcinomas, myleoid disorders or adenomas.

82. A method as in claim 75 for the treatment of carcinomas, myleoid disorders or adenomas.

83. A method as in claim 76 for the treatment of carcinomas, myleoid disorders or adenomas.

84. A method as in claim 77 for the treatment of carcinomas, myleoid disorders or adenomas.

85. A method as in claim 78 for the treatment of carcinomas, myleoid disorders or adenomas.

86. A method as in claim 79 for the treatment of carcinomas, myleoid disorders or adenomas.

87. A method as in claim 74 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

88. A method as in claim 75 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

89. A method as in claim 76 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

90. A method as in claim 77 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

91. A method as in claim 78 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

92. A method as in claim 79 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

93. A method as in claim 74 for the treatment of myeloid leukemia or villous colon adenomas.

94. A method as in claim 75 for the treatment of myeloid leukemia or villous colon adenomas.

95. A method as in claim 76 for the treatment of myeloid leukemia or villous colon adenomas.

96. A method as in claim 77 for the treatment of myeloid leukemia or villous colon

adenomas.

97. A method as in claim 78 for the treatment of myeloid leukemia or villous colon adenomas.

98. A method as in claim 79 for the treatment of myeloid leukemia or villous colon adenomas.--

REMARKS

Support for new claims 68-73 is found in Examples numbers 5, 13, 42, 43 and 98. Methods for preparing these compounds is found on pages 57, 59, 66 and 78. Support for new claims 74-98 is found on page 2, lines 21-24 and page 11, lines 9 through page 14, line 30.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
(703) 812-5310 [Direct Dial]
E-mail address: traverso@mwzb.com

Filed: November 27, 2001

RJT/lvb
K:\Bayer\18A\prel amend 11-27-01.wpd